Receptor tyrosine kinases: mechanisms of activation and signaling

Current Opinion in Cell Biology

Volumn 19, Issue 2, 2007, Pages 117-123

  Hubbard, Stevan R ^a   Miller, W Todd ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

CELL COMMUNICATION; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL MOTILITY; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVATION; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SUBSTRATE COMPLEX; HUMAN; LIGAND BINDING; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURAL PROTEOMICS;

ANIMALS; COENZYMES; ENZYME ACTIVATION; HUMANS; LIGANDS; MODELS, BIOLOGICAL; PROTEIN CONFORMATION; RECEPTOR CROSS-TALK; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 33847696075     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceb.2007.02.010     Document Type: Review

References (51)

1. Robinson D.R., Wu Y.M., and Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene 19 (2000) 5548-5557
2. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 (2001) 355-365
3. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 (2000) 211-225
4. Hubbard S.R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol 5 (2004) 464-471
5. Pawson T., Gish G.D., and Nash P. SH2 domains, interaction modules and cellular wiring. Trends Cell Biol 11 (2001) 504-511
6. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J., Lemmon M.A., Sliwkowski M.X., Ward C.W., and Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12 (2003) 541-552
7. Moriki T., Maruyama H., and Maruyama I.N. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol 311 (2001) 1011-1026
8. Teramura Y., Ichinose J., Takagi H., Nishida K., Yanagida T., and Sako Y. Single-molecule analysis of epidermal growth factor binding on the surface of living cells. EMBO J 25 (2006) 4215-4222. This single-molecule fluorescence study provides quantitative kinetic parameters for the activation of EGFR by EGF.
9. Özcan F., Klein P., Lemmon M.A., Lax I., and Schlessinger J. On the nature of low- and high-affinity EGF receptors on living cells. Proc Natl Acad Sci USA 103 (2006) 5735-5740
10. Zhang X., Gureasko J., Shen K., Cole P.A., and Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125 (2006) 1137-1149. This structural and biochemical study establishes that the EGFR kinase is activated through an allosteric mechanism resembling activation of CDK2 by cyclin A. This study also establishes that the inactive state of the EGFR kinase is Src-like.
11. Jeffrey P.D., Russo A.A., Polyak K., Gibbs E., Hurwitz J., Massague J., and Pavletich N.P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376 (1995) 313-320
12. Gherardi E., Sandin S., Petoukhov M.V., Finch J., Youles M.E., Ofverstedt L.G., Miguel R.N., Blundell T.L., Vande Woude G.F., Skoglund U., et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci USA 103 (2006) 4046-4051. Electron microscopy and small-angle x-ray scattering data are used to develop a structural model for the active 2:2 HGF-Met complex.
13. Wang W., Marimuthu A., Tsai J., Kumar A., Krupka H.I., Zhang C., Powell B., Suzuki Y., Nguyen H., Tabrizizad M., et al. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc Natl Acad Sci USA 103 (2006) 3563-3568
14. Mohammadi M., Olsen S.K., and Ibrahimi O.A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16 (2005) 107-137
15. Olsen S.K., Li J.Y., Bromleigh C., Eliseenkova A.V., Ibrahimi O.A., Lao Z., Zhang F., Linhardt R.J., Joyner A.L., and Mohammadi M. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev 20 (2006) 185-198
16. McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E., Lovrecz G.O., Elleman T.C., Richards K.M., Bentley J.D., Pilling P.A., et al. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 443 (2006) 218-221. Using two different Fab antibody fragments, the entire ectodomain of the insulin receptor is crystallized and its three-dimensional structure solved. Although the structure lacks insulin, it spatially establishes the domain organization within the ectodomain.
17. Schlee S., Carmillo P., and Whitty A. Quantitative analysis of the activation mechanism of the multicomponent growth-factor receptor Ret. Nat Chem Biol 2 (2006) 636-644. Using binding and phosphorylation measurements from live cells, along with mathematical modeling, the authors provide a quantitative description of the formation of the ART-Ret-GFRα3 signaling complex.
18. Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S., Santoro M., Ibanez C.F., and McDonald N.Q. Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281 (2006) 33577-33587
19. Stiegler A.L., Burden S.J., and Hubbard S.R. Crystal structure of the agrin-responsive immunoglobulin-like domains 1 and 2 of the receptor tyrosine kinase MuSK. J Mol Biol 364 (2006) 424-433
20. Hu J., Liu J., Ghirlando R., Saltiel A.R., and Hubbard S.R. Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor. Mol Cell 12 (2003) 1379-1389
21. Depetris R.S., Hu J., Gimpelevich I., Holt L.J., and Hubbard S.R. Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14. Mol Cell 20 (2005) 325-333. The crystal structure of the complex between the insulin receptor kinase and the BPS region of Grb14 illuminates the mechanism by which Grb14 functions as a negative regulator of insulin signaling; the BPS region acts as a pseudosubstrate inhibitor.
22. Cooney G.J., Lyons R.J., Crew A.J., Jensen T.E., Molero J.C., Mitchell C.J., Biden T.J., Ormandy C.J., James D.E., and Daly R.J. Improved glucose homeostasis and enhanced insulin signalling in Grb14-deficient mice. EMBO J 23 (2004) 582-593
23. Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res 284 (2003) 66-77
24. Sardi S.P., Murtie J., Koirala S., Patten B.A., and Corfas G. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 127 (2006) 185-197
25. Pasquale E.B. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6 (2005) 462-475
26. Hattori M., Osterfield M., and Flanagan J.G. Regulated cleavage of a contact-mediated axon repellent. Science 289 (2000) 1360-1365
27. Janes P.W., Saha N., Barton W.A., Kolev M.V., Wimmer-Kleikamp S.H., Nievergall E., Blobel C.P., Himanen J.P., Lackmann M., and Nikolov D.B. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123 (2005) 291-304. This study provides mechanistic details governing ADAM10 cleavage of ephrinA5-EphA4, which underlies cell-cell repulsion as mediated by ephrin-Eph interactions.
28. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol 7 (2006) 952-958
29. Blagoev B., Ong S.E., Kratchmarova I., and Mann M. Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics. Nat Biotechnol 22 (2004) 1139-1145. This paper describes the first in-depth study of the temporal dimension of the EGFR signaling network, using the SILAC proteomic approach. The authors study the tyrosine phosphorylation status of a number of proteins after stimulation with EGF for various periods of time.
30. Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J., Lauffenburger D.A., and White F.M. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics 4 (2005) 1240-1250. A chemical derivatization strategy is used to study tyrosine phosphorylated proteins in EGF-stimulated cells.
31. Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., and Mann M. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127 (2006) 635-648. An expanded proteomics study of the EGF signaling network in which the phosphorylation of 2,244 proteins at 6,600 tyrosine, serine, and threonine sites is reported. The data from this study have been compiled into a publicly accessible database called Phosida (http://www.phosida.com).
32. Zhang G., Spellman D.S., Skolnik E.Y., and Neubert T.A. Quantitative phosphotyrosine proteomics of EphB2 signaling by stable isotope labeling with amino acids in cell culture (SILAC). J Proteome Res 5 (2006) 581-588
33. Schmelzle K., Kane S., Gridley S., Lienhard G.E., and White F.M. Temporal dynamics of tyrosine phosphorylation in insulin signaling. Diabetes 55 (2006) 2171-2179
34. Bose R., Molina H., Patterson A.S., Bitok J.K., Periaswamy B., Bader J.S., Pandey A., and Cole P.A. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci U S A 103 (2006) 9773-9778
35. Mukherji M., Brill L.M., Ficarro S.B., Hampton G.M., and Schultz P.G. A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways. Biochemistry 45 (2006) 15529-15540
36. Jones R.B., Gordus A., Krall J.A., and MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439 (2006) 168-174. Protein microarrays are used to measure the strength of interaction between purified SH2 or PTB domains and phosphotyrosine-containing peptides representing the autophosphorylation sites on ErbB1-4. The data reveal the degree of selectivity for different autophosphorylation sites at different thresholds of affinity.
37. Dierck K., Machida K., Voigt A., Thimm J., Horstmann M., Fiedler W., Mayer B.J., and Nollau P. Quantitative multiplexed profiling of cellular signaling networks using phosphotyrosine-specific DNA-tagged SH2 domains. Nat Methods 3 (2006) 737-744
38. Friedman A., and Perrimon N. A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling. Nature 444 (2006) 230-234. A functional genomics study in D. melanogaster cells that identifies genes involved in positive or negative regulation of ERK following RTK stimulation.
39. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
40. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289 (2000) 1938-1942
41. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
42. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
43. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004) 13306-13311
44. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
45. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352 (2005) 786-792
46. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs III W.H., Edeen P.T., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102 (2005) 11011-11016
47. Okram B., Nagle A., Adrian F.J., Lee C., Ren P., Wang X., Sim T., Xie Y., Xia G., Spraggon G., et al. A general strategy for creating 'inactive-conformation' abl inhibitors. Chem Biol 13 (2006) 779-786. A structure-based drug design study is reported that describes how novel ATP-competitive inhibitors can be designed to target the inactive conformation of protein kinases, in this case Abl; in general, inactive-state inhibitors exhibit higher specificity and affinity than active-state inhibitors.
48. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110 (2002) 775-787
49. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., and Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11 (2003) 507-517
50. Stamos J., Sliwkowski M.X., and Eigenbrot C. Structure of the EGF receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 23 (2002) 23
51. Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., Scheibe D.N., Snell G.P., Zou H., Sang B.C., and Wilson K.P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279 (2004) 31655-31663